microRNA Replacement Therapy
Scientific Advisors

Dr. Corey Goodman is a Managing Partner of venBio, a private equity firm specializing in life sciences and an Adjunct Professor at UC Berkeley. Dr. Goodman serves as Chairman of the board of directors of Second Genome, Oligasis, Solstice Biologics, Heart Metabolics, and Alexo Therapeutics and is a member of the board of directors of Checkmate Pharmaceuticals. Previously, Dr. Goodman co-founded each of Alexo, Labrys Biologics, Second Genome, Solstice, Exelixis, and Renovis, and served as CEO of Renovis. Dr. Goodman was the President of the Pfizer, Biotherapeutics and Bioinnovation Center. Dr. Goodman is an elected member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society. Dr. Goodman is Chair of the California Council on Science and Technology, and previously served as the Chair of the National Research Council’s Board on Life Sciences. Goodman previously served as a member of the board of directors of Mirna Therapeutics.
Mirna-Michael Powell
Dr. Flaherty has served as Director of the Henri and Belinda Termeer Center for Targeted Therapy since 2012 and Director of Clinical Research at the Massachusetts General Hospital since 2014. Dr. Flaherty’s research and clinical focus is therapies for melanoma, with a particular expertise in targeted therapies. He is a Professor of Medicine at Harvard Medical School and has authored and co-authored nearly 200 peer-reviewed reports and articles including a series in The New England Journal of Medicine. Notably, Dr. Flaherty is the principal investigator of the NCI MATCH trial, the first NCI-sponsored trial assigning patients to targeted therapy independent of tumor type on the basis of DNA sequencing detection of oncogenes. Dr. Flaherty is the Chair of the Developmental Therapeutics Committee for the Eastern Cooperative Oncology Group (ECOG) and in 2013, was appointed as its Deputy Chair for Biomarker Science.

Mirna-Michael Powell
Dr. David H. Johnson is the Chairman of the Department of Internal Medicine at the University of Texas Southwestern Medical School in Dallas, Texas, and the Donald W. Seldin Distinguished Chair in Internal Medicine. Dr. Johnson served on the board of directors of the American Society of Clinical Oncology (ASCO), the American Board of Internal Medicine, the National Comprehensive Cancer Network (NCCN). Dr. Johnson also served on the Oncology Drug Advisory Committee (ODAC) at the Food and Drug Administration (FDA). Dr. Johnson is a recognized specialist in the area of non-small cell lung cancer.
Mirna-Michael Powell
Dr. Art Krieg serves as Founder and CEO at Checkmate Pharmaceuticals, and has worked in the oligonucleotide field since the 1980s. He co-founded Coley Pharmaceutical Group and served as the Chief Scientific Officer of Pfizer’s Oligonucleotide Therapeutics Unit. Dr. Krieg subsequently co-founded RaNA Therapeutics, and served as CSO at Sarepta Therapeutics. He co-founded the first antisense journal, Nucleic Acid Therapeutics, and the Oligonucleotide Therapeutic Society, for which he is currently President-elect.

Mirna-Michael Powell
Dr. Frank J. Slack is the Director of the Institute for RNA Medicine in the Department of Pathology at BIDMC Cancer Center/Harvard Medical School. The Slack laboratory studies the roles of microRNAs and their targets in cancer, development and aging. He started work on microRNAs as a postdoctoral fellow in Dr. Gary Ruvkun’s laboratory at Harvard Medical School, where he co-discovered let-7, the first known human microRNA.

Mirna-Michael Powell
Dr. Daniel D. Von Hoff is currently Physician in Chief, Distinguished Professor of Translational Research at TGen, and Chief Scientific Officer for US Oncology and for Scottsdale Healthcare’s Clinical Research Institute. He was appointed to President Bush’s National Cancer Advisory Board. Dr. Von Hoff is also the past President of the American Association for Cancer Research (AACR), was on the AACR and the American Society of Clinical Oncology's Board of Directors, and is a fellow of the American College of Physicians.
Mirna-Michael Powell
Dr. Steve Weitman is a Professor at the Institute for Drug Development at the Cancer Therapy and Research Center in San Antonio. Dr. Weitman was Chief Medical Officer and Member of the Executive Committee at ILEX Oncology and led development and FDA approval of clofarabine. He was an Associate Editor of Investigational New Drugs.



© 2015 Mirna Therapeutics, Inc. All Rights Reserved.